Alzheimer's
Physician critiques new Alzheimer's drug approval
Iniulat ng AI
In an opinion piece published on MedPage Today, oncologist Vinay Prasad argues that the FDA's approval of lecanemab for Alzheimer's disease is premature and overlooks significant risks. He calls for more rigorous evidence before widespread use.
Toxic alliance of proteins may trigger Alzheimer's disease
Researchers at Rockefeller University have identified a harmful interaction between amyloid beta and fibrinogen that forms stubborn clots, damaging brain blood vessels and sparking inflammation even at low concentrations. This complex disrupts the blood-brain barrier and leads to early signs of neurodegeneration. The findings suggest a new target for early intervention in Alzheimer's disease.
Enhanced vitamin K analogues boost neuron regeneration
Researchers in Japan have developed synthetic vitamin K compounds that are three times more effective than natural versions at promoting neuron growth. These analogues, combined with retinoic acid, could offer new treatments for neurodegenerative diseases like Alzheimer's. The study highlights their ability to cross the blood-brain barrier and activate key brain receptors.
Scientists reverse brain aging in mice using stem cells
Researchers at Cedars-Sinai have developed young immune cells from human stem cells that reversed signs of aging and Alzheimer's disease in mice. The treatment improved memory and brain structure in the animals. The findings, published in Advanced Science, suggest potential for personalized therapies against cognitive decline.